Trial Profile
A Multicenter, Open-label, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Sufentanil Transdermal System (TDS) With Sustained-Release Morphine Sulfate in Patients With Chronic Pain Due to Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2015
Price :
$35
*
At a glance
- Drugs Sufentanil (Primary) ; Morphine
- Indications Cancer pain
- Focus Therapeutic Use
- 01 Jul 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record